|
1.
|
|
17 p, 345.4 KB |
Bone sarcomas : ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
/
Casali, P.G. (University of Milan) ;
Bielack, Stefan S (Klinikum Stuttgart-Olgahospital) ;
Abecassis, N. (Instituto Portugues de Oncologia de Lisboa Francisco Gentil EPE) ;
Aro, H.T. (Turku University Hospital (Turun Yliopistollinen Keskussairaala)) ;
Bauer, S. (University Hospital Essen (Alemanya)) ;
Biagini, Roberto (Regina Elena National Cancer Institute) ;
Bonvalot, S. (Institut Curie) ;
Boukovinas, I. (Bioclinic Thessaloniki) ;
Bovee, J.V.M.G. (Leiden University Medical Center) ;
Brennan, B. (Royal Manchester Children's Hospital) ;
Brodowicz, Thomas (Medizinische Universität Wien) ;
Broto, J.M. (Hospital Universitario Virgen Del Rocio-CIBERONC) ;
Brugières, L. (Gustave Roussy Cancer Campus) ;
Buonadonna, A. (Centro di Riferimento Oncologico di Aviano) ;
De Alava, E (Universidad de Sevilla) ;
Dei Tos, A.P. (Ospedale Regionale di Treviso S.Maria di Cà Foncello) ;
Del Muro, X.G. (Integrated Unit ICO Hospitalet) ;
Dileo, P. (University College London Hospitals NHS Trust) ;
Dhooge, C. (Universitair Ziekenhuis Gent) ;
Eriksson, M. (Skåne University Hospital (Suècia)) ;
Fagioli, F. (University of Turin) ;
Fedenko, A. (N. N. Blokhin Russian Cancer Research Center) ;
Ferraresi, V. (Regina Elena National Cancer Institute) ;
Ferrari, A. (Fondazione IRCCS Istituto Nazionale Dei Tumori) ;
Ferrari, S. (Istituto Ortopedico Rizzoli) ;
Frezza, A.M. (Istituto Nazionale Dei Tumori) ;
Gaspar, N. (Gustave Roussy Cancer Campus) ;
Gasperoni, S. (Azienda Ospedaliera Universitaria Careggi Firenze) ;
Gelderblom, H. (Leiden University Medical Centre) ;
Gil, T. (Institut Jules Bordet) ;
Grignani, G. (Candiolo Cancer Institute) ;
Gronchi, A. (University of Milan) ;
Haas, R.L. (Leiden University Medical Centre) ;
Hassan, B. (Oxford University Hospitals NHS Foundation Trust) ;
Hecker-Nolting, S. (Klinikum Stuttgart-Olgahospital) ;
Hohenberger, P. (Mannheim University Medical Center) ;
Issels, R. (University Munich) ;
Joensuu, H. (Helsinki University Central Hospital (HUCH)) ;
Jones, R.L. (Royal Marsden Hospital (Regne Unit)) ;
Judson, I. (Institute of Cancer Research) ;
Jutte, P. (University Medical Center Groningen) ;
Kaal, S. (Radboud University Medical Center) ;
Kager, L. (St. Medical University Vienna) ;
Kasper, B. (Mannheim University Medical Center) ;
Kopeckova, K. (University Hospital Motol) ;
Krákorová, D.A. (Masaryk Memorial Cancer Institute) ;
Ladenstein, R. (Medical University Vienna) ;
Le Cesne, A. (Gustave Roussy Cancer Campus) ;
López Pousa, Antonio (Institut d'Investigació Biomèdica Sant Pau) ;
Lugowska, I. (Maria Skłodowska Curie Institute-Oncology Centre) ;
Merimsky, O. (Tel Aviv Sourasky Medical Center (Ichilov)) ;
Montemurro, M. (Medical Oncology University Hospital of Lausanne) ;
Morland, B. (Birmingham Women's and Children's NHS Foundation Trust) ;
Pantaleo, M.A. (Policlinico S Orsola-Malpighi Università di Bologna) ;
Piana, R. (University of Turin) ;
Picci, P. (Istituto Ortopedico Rizzoli) ;
Piperno-Neumann, S. (Institut Curie) ;
Reichardt, P. (Helios Klinikum Berlin Buch) ;
Robinson, M.H. (Weston Park Hospital NHS Trust) ;
Rutkowski, P. (Maria Skłodowska Curie Institute-Oncology Centre) ;
Safwat, A.A. (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Schöffski, P. (University Hospitals Leuven (Bèlgica)) ;
Sleijfer, S. (Erasmus MC Cancer Institute) ;
Stacchiotti, S. (Istituto Nazionale Dei Tumori) ;
Strauss, S.J. (University College London Hospitals NHS Trust) ;
Sundby Hall, K. (Norwegian Radium Hospital) ;
Unk, M. (Institute of Oncology of Ljubljana) ;
Van Coevorden, F. (Netherlands Cancer Institute Antoni Van Leeuwenhoek) ;
Van Der Graaf, W.T.A. (Netherlands Cancer Institute Antoni Van Leeuwenhoek) ;
Whelan, J. (Sarcoma Unit. University College London Hospitals NHS Trust) ;
Wardelmann, E. (Universitätsklinikum Münster) ;
Zaikova, O. (Oslo University Hospital (Oslo, Noruega)) ;
Blay, Jean-Yves (Centre Leon Bernard and UCBL1) ;
Universitat Autònoma de Barcelona
2018 -  10.1093/annonc/mdy310
Annals of oncology, Vol. 29 (january 2018) , p. iv79-iv95
|
|
|
2.
|
|
11 p, 1.4 MB |
Prognostic gene expression signature for high-grade serous ovarian cancer
/
Millstein, Joshua (University of Southern California) ;
Budden, Timothy (The University of Manchester) ;
Goode, Ellen L. (Mayo Clinic) ;
Anglesio, Michael (University of British Columbia) ;
Talhouk, Aline (University of British Columbia) ;
Intermaggio, Maria Paola (University of NSW Sydney) ;
Leong, Hueisan (Peter MacCallum Cancer Center) ;
Chen, Stephanie S. (Cedars-Sinai Medical Center) ;
Elatre, Wafaa A. (University of Southern California) ;
Gilks, Cyril Blake (University of British Columbia) ;
Nazeran, Tayyebeh M. (University of British Columbia) ;
Volchek, Mila (Royal Women's Hospital) ;
Bentley, Rex C. (Duke University Hospital) ;
Wang, Chen (Mayo Clinic) ;
Chiu, Derek S. (University of British Columbia) ;
Kommoss, Stefan (Tuebingen University Hospital) ;
Leung, Samuel C. Y. (University of British Columbia) ;
Senz, Janine (University of British Columbia) ;
Lum, Amy (University of British Columbia) ;
Chow, Veronica (University of British Columbia) ;
Sudderuddin, Hanwei (University of British Columbia) ;
Mackenzie, Robertson (University of British Columbia) ;
George, Joshy (The Jackson Laboratory for Genomic Medicine) ;
Fereday, Sian (University of Melbourne) ;
Hendley, Joy (University of Melbourne) ;
Traficante, Nadia (University of Melbourne) ;
Steed, Helen (Royal Alexandra Hospital) ;
Koziak, Jennifer M. (Alberta Health Services-Cancer Care) ;
Köbel, Martin (Foothills Medical Center) ;
McNeish, Iain (University of Glasgow) ;
Goranova, Teodora Evgenieva (University of Cambridge) ;
Ennis, Darren P. (University of Glasgow) ;
Macintyre, Geoff (University of Cambridge) ;
Silva De Silva, D. (University of Cambridge) ;
Ramon y Cajal, Teresa (Institut d'Investigació Biomèdica Sant Pau) ;
García Donas, J. (HM Hospitales D Centro Integral Oncológico HM Clara Campal) ;
Hernando, Susana (Hospital Universitario Funcacion Alcorcon) ;
Rodriguez, Gustavo C. (University of Chicago) ;
Cushing-Haugen, Kara L. (Fred Hutchinson Cancer Research Center) ;
Harris, Holly Ruth (University of Washington) ;
Greene, Casey S. (University of Pennsylvania) ;
Zelaya, René A. (Geisel School of Medicine at Dartmouth) ;
Behrens, Sabine (German Cancer Research Center (DKFZ)) ;
Fortner, Renée T. (German Cancer Research Center (DKFZ)) ;
Sinn, Hans-Peter (Heidelberg University Hospital (Alemanya)) ;
Herpel, Esther (University Hospital and German Cancer Research Center) ;
Lester, Jenny (Cedars-Sinai Medical Center) ;
Lubinski, Jan (Pomeranian Medical University) ;
Oszurek, Oleg (Pomeranian Medical University) ;
Tołoczko, Aleksandra D. (Pomeranian Medical University) ;
Cybulski, Cezary (Pomeranian Medical University) ;
Menkiszak, Janusz Leszek (Pomeranian Medical University) ;
Pearce, Celeste Leigh (University of Southern California Norris Comprehensive Cancer Center) ;
Pike, Malcolm C. (Memorial Sloan-Kettering Cancer Center (Nova York, Estats Units d'Amèrica)) ;
Tseng, Chiuchen Cheng (University of Southern California) ;
Alsop, Jennifer (University of Cambridge) ;
Rhenius, Valerie (University of Cambridge) ;
Song, Hongan (University of Cambridge) ;
Jimenez-Liñan, Mercedes (Addenbrooke's Hospital NHS Trust) ;
Piskorz, Anna M. (University of Cambridge) ;
Gentry-Maharaj, Aleksandra (University College London) ;
Karpinskyj, Chloe (University College London) ;
Widschwendter, M. (University College London) ;
Singh, Naveena K. (Barts Health National Health Service Trust) ;
Kennedy, Catherine J. (Westmead Hospital) ;
Harnett, Paul R. (University of Sidney) ;
Gao, Bo (Westmead Hospital) ;
Johnatty, Sharon E. (QIMR Berghofer Medical Research Institute (Brisbane, Austràlia)) ;
Sayer, Robyn A. (Westmead Hospital) ;
Boros, Jessica (Westmead Hospital) ;
Winham, Stacey J. (Mayo Clinic) ;
Keeney, Gary L. (Mayo Clinic) ;
Kaufmann, Scott H. (Mayo Clinic) ;
Larson, Melissa C. (Mayo Clinic) ;
Luk, Hugh W. (University of Hawaii Cancer Center) ;
Hernandez, Brenda Y. (University of Hawaii Cancer Center) ;
Thompson, Pamela J. (Cedars-Sinai Medical Center) ;
Wilkens, Lynne Ross (University of Hawaii Cancer Center) ;
Carney, Michael E. (University of Hawaii) ;
Trabert, Britton (National Cancer Institute) ;
Lissowska, Jolanta (M Sklodowska Curie National Research Institute of Oncology) ;
Brinton, Louise Annette (National Cancer Institute) ;
Sherman, Mark E. (Mayo Clinic College of Medicine) ;
Bodelón, Clara (National Cancer Institute) ;
Hinsley, Samantha (University of Glasgow) ;
Lewsley, Liz Anne (University of Glasgow) ;
Glasspool, Rosalind M. (University of Glasgow) ;
Banerjee, Susana (The Royal Marsden NHS Foundation Trust and Institute of Cancer Research) ;
Stronach, Euan A. (Imperial College London) ;
Haluska, Paul J. (Mayo Clinic) ;
Ray-Coquard, Isabelle Laure (Centre Leon Berard and University Claude Bernard Lyon 1) ;
Mahner, Sven (LMU Munich) ;
Winterhoff, Boris J. N. (University of Minnesota) ;
Slamon, Dennis J. (University of California at Los Angeles) ;
Levine, Douglas A. (NYU Langone Medical Center) ;
Kelemen, Linda E. (Medical University of South Carolina) ;
Benitez, Javier J. (Centro Nacional de Investigaciones Oncológicas) ;
Chang-Claude, J. (University Medical Center Hamburg-Eppendorf) ;
Gronwald, Jacek (Pomeranian Medical University) ;
Wu, Anna H. (University of Southern California) ;
Menon, Usha (MRC University College London) ;
Goodman, Marc T. (Cedars-Sinai Medical Center) ;
Schildkraut, Joellen M. (Emory University) ;
Wentzensen, Nicolas A. (National Cancer Institute) ;
Brown, Robert (Imperial College London) ;
Berchuck, Andrew (Duke University Hospital) ;
Gayther, Simon A. (Cedars-Sinai Medical Center) ;
García, M. J. (Centro de Investigación Biomédica en Red de Enfermedades Raras) ;
Henderson, Michelle J. (University of NSW Sydney) ;
Rossing, Mary Anne (University of Washington) ;
Beeghly-Fadiel, Alicia (Vanderbilt University School of Medicine) ;
Fasching, Peter Andreas (Friedrich-Alexander-University Erlangen-Nuremberg) ;
Orsulic, Sandra (Cedars-Sinai Medical Center) ;
Karlan, Beth Y. (Cedars-Sinai Medical Center) ;
Konecny, Gottfried Ewald (University of California at Los Angeles) ;
Huntsman, David G. (BC Cancer Research Centre) ;
Brenton, James D. (University of Cambridge) ;
Doherty, Jennifer Anne (University of Utah) ;
Pharoah, Paul D. P. (University of Cambridge) ;
Ramus, Susan (University of NSW Sydney) ;
Universitat Autònoma de Barcelona
Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. [...]
2020 - 10.1016/j.annonc.2020.05.019
Annals of oncology, Vol. 31 Núm. 9 (01 2020) , p. 1240-1250
|
|
|
3.
|
|
10 p, 564.4 KB |
Accuracy and Survival Outcomes after National Implementation of Sentinel Lymph Node Biopsy in Early Stage Endometrial Cancer
/
Cabrera Díaz, Silvia (Hospital Universitari Vall d'Hebron) ;
Gómez-Hidalgo, Natalia R (Hospital Universitari Vall d'Hebron) ;
Bebia, Vicente (Hospital Universitari Vall d'Hebron) ;
Fernández-González, Sergi (Hospital Universitari de Bellvitge) ;
Fusté, Pere (Hospital Clínic i Provincial de Barcelona) ;
Martínez, Sergio (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Gil-Moreno, Antonio 1965- (Hospital Universitari Vall d'Hebron) ;
Universitat Autònoma de Barcelona
Sentinel lymph node (SLN) biopsy has recently been accepted to evaluate nodal status in endometrial cancer at early stage, which is key to tailoring adjuvant treatments. Our aim was to evaluate the national implementation of SLN biopsy in terms of accuracy to detect nodal disease in a clinical setting and oncologic outcomes according to the volume of nodal disease. [...]
Springer New York, 2023 - 10.1245/s10434-023-14068-0
Annals of Surgical Oncology
|
|
|
4.
|
|
0 p, 567.1 KB |
Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer : clinical and biomarker results from a phase I trial
/
Schuler, M. (German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany) ;
Berardi, R. (Università Politecnica delle Marche-Ospedali Riuniti) ;
Lim, W.-T (National Cancer Centre Singapore) ;
de Jonge, M. (Erasmus MC Cancer Center, Rotterdam) ;
Bauer, Todd M (Sarah Cannon Research Institute, and Tennessee Oncology) ;
Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ;
Gottfried, M. (Oncology Institute of Meir Medical Center) ;
Han, J.Y (Center for Lung Cancer, National Cancer Center (Corea del Sud)) ;
Lee, D. H. (University of Ulsan College of Medicine (República de Corea)) ;
Wollner, M. (Rambam Health Care Campusm (Israel)) ;
Hong, David (MD Anderson Cancer Center (Estats Units d'Amèrica)) ;
Vogel, A. (Hannover Medical School (Alemanya)) ;
Delmonte, A. (Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori) ;
Akimov, Mikhail (Novartis Pharma (Siïssa)) ;
Ghebremariam, S. (Oncology Global Development-BDM) ;
Cui, X. (Novartis Institutes for Biomedical Research) ;
Nwana, N. (Oncology Precision Medicine) ;
Giovannini, M. (Novartis Pharmaceuticals Corporation(Estats Units d'Amèrica)) ;
Kim, T. M. (Seoul National University Hospital)
Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs in 3%-4% of non-small-cell lung cancer (NSCLC) and is associated with unfavorable prognosis. While MET is a validated drug target in lung cancer, the best biomarker strategy for the enrichment of a susceptible patient population still remains to be defined. [...]
2020 - 10.1016/j.annonc.2020.03.293
Annals of oncology, Vol. 31 (march 2020) , p. 789-797
|
|
|
5.
|
|
11 p, 2.6 MB |
Development of adaptive immune effector therapies in solid tumors
/
Comoli, P. (Cell Factory and Pediatric Hematology Oncology. Fondazione IRCCS Policlinico San Matteo) ;
Chabannon, Christian (Institut Paoli-Calmettes. Aix-Marseille University. INSERM CBT 1409. Centre for Clinical Investigation in Biotherapy) ;
Koehl, U. (Institute of Cellular Therapeutics. Hannover Medical School) ;
Lanza, F. (Hematology and Stem Cell Transplant. Romagna Transplant Network) ;
Urbano Ispizua, Álvaro (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Hudecek, M. (University Hospital Würzburg) ;
Ruggeri, Annalisa (Ospedale Pediatrico Bambino Gesù (Roma, Itàlia)) ;
Secondino, S. (Università degli Studi di Pavia. Dipartimento di Medicina Interna e Terapia Medica) ;
Bonini, C. (University Vita-Salute San Raffaele) ;
Pedrazzoli, P. (Università degli Studi di Pavia. Dipartimento di Medicina Interna e Terapia Medica) ;
Universitat Autònoma de Barcelona
State-of-the-art treatment strategies have drastically ameliorated the outcome of patients affected by cancer. However, resistant and recurrent solid tumors are generally nonresponsive to conventional therapies. [...]
2019 - 10.1093/annonc/mdz285
Annals of oncology, Vol. 30 Núm. 11 (november 2019) , p. 1740-1750
|
|
|
6.
|
|
8 p, 256.7 KB |
Effect of protocol-related variables and women's characteristics on the cumulative false-positive risk in breast cancer screening
/
Román, R. (Institut Municipal d'Investigació Mèdica (Barcelona, Catalunya)) ;
Sala, Maria (Institut Municipal d'Investigació Mèdica (Barcelona, Catalunya)) ;
Salas, D. (Centre Superior d'Investigació en Salut Pública, València) ;
Ascunce, Nieves (Instituto de Salud Pública de Navarra) ;
Zubizarreta Alberdi, Raquel (Conselleria de Sanidade de la Xunta de Galicia) ;
Castells, Xavier (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)
Background: Reducing the false-positive risk in breast cancer screening is important. We examined how the screening-protocol and women's characteristics affect the cumulative false-positive risk. Methods: This is a retrospective cohort study of 1 565 364 women aged 45-69 years who underwent 4 739 498 screening mammograms from 1990 to 2006. [...]
2011 - 10.1093/annonc/mdr032
Annals of oncology, Vol. 23 (march 2011) , p. 104-111
|
|
|
7.
|
|
8 p, 712.6 KB |
Biomarker analysis beyond angiogenesis : RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
/
Yoshino, Takayuki (National Cancer Center Hospital East, Kashiwa, Japan) ;
Portnoy, D. C. (The West Clinic, Memphis, USA) ;
Obermannová, R. (Masarykuv Onkologicky Ustav, Brno, Czech Republic) ;
Bodoky, G. (St László Hospital (Hongria)) ;
Prausová, J. (Fakultni Nemocnice v MOTOLE, Prague, Czech Republic) ;
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid)) ;
Ciuleanu, Tudor Eliade (Institutul Oncologic Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania) ;
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ;
Cohn, A. L. (Rocky Mountain Cancer Center, LLP, Denver, USA) ;
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Yamazaki, K. (Shizuoka Cancer Center, Shizuoka, Japan) ;
Lonardi, Sara (Istituto Oncologico Veneto-IRCCS, Padova, Italy) ;
Muro, K. (Aichi Cancer Center Hospital) ;
Kim, T. W. (Asan Medical Center, University of Ulsan, Seoul, Republic of Korea) ;
Yamaguchi, K. (The Cancer Institute Hospital of JFCR, Tokyo, Japan) ;
Grothey, A. (Mayo Clinic, Phoenix, USA) ;
O'Connor, J. (Instituto Alexander Fleming (Buenos Aires, Argentina)) ;
Taieb, Julien (Sorbonne Paris Cité, Paris Descartes University, Georges Pompidou European Hospital, Paris, France) ;
Wijayawardana, S. R. (Eli Lilly and Company, Indianapolis, USA) ;
Hozak, Rebecca R (Eli Lilly and Company, Indianapolis, USA) ;
Nasroulah, F. (Eli Lilly and Company, Buenos Aires, Argentina) ;
Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Vall d'Hebron Institut d'Oncologia
: Second-line treatment with ramucirumab+FOLFIRI improved overall survival (OS) versus placebo+FOLFIRI for patients with metastatic colorectal carcinoma (CRC) [hazard ratio (HR)=0. 84, 95% CI 0. 73-0. [...]
2018 - 10.1093/annonc/mdy461
Annals of oncology, Vol. 30 (october 2018) , p. 124-131
|
|
|
8.
|
|
9 p, 325.6 KB |
Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1) : a phase III, international, randomized, placebo-controlled study
/
Van Cutsem, E. (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Yoshino, Takayuki (Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan) ;
Lenz, H. J. (Division of Medical Oncology, Norris Comprehensive Cancer Center, Los Angeles, USA) ;
Lonardi, Sara (Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto - IRCCS, Padua) ;
Falcone, Alfredo (Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy) ;
Limón, M. L. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Saunders, M. (Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK) ;
Sobrero, A. (Department of Medical Oncology, Azienda Ospedaliera San Martino, Genoa, Italy) ;
Park, Y S. (Department of Hematology and Oncology, Samsung Medical Center, Seoul, South Korea) ;
Ferreiro, R. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Hong, Y S. (Department of Oncology, Asan Medical Center, Seoul, South Korea) ;
Tomasek, J. (Masaryk Memorial Cancer Institute (Brno, República Txeca)) ;
Taniguchi, H. (Aichi Cancer Center Hospital) ;
Ciardiello, Fortunato (Oncologia Medica, Seconda Università deli Studi di Napoli, Naples, Italy) ;
Stoehr, J. (Boehringer Ingelheim, Pharma GmbH & Co. KG, Biberach, Germany) ;
Oum'Hamed, Z. (Boehringer Ingelheim France S.A.S, Reims, France) ;
Vlassak, S. (SCS Boehringer Ingelheim Comm.V, Brussels, Belgium) ;
Studeny, M. (Division of Medicine/Clinical Development Department, Boehringer Ingelheim, Vienna, Austria) ;
Argiles, G.. (Vall d'Hebron Institut d'Oncologia) ;
Universitat Autònoma de Barcelona
Angiogenesis is critical to colorectal cancer (CRC) growth and metastasis. Phase I/II studies have demonstrated the efficacy of nintedanib, a triple angiokinase inhibitor, in patients with metastatic CRC. [...]
2018 - 10.1093/annonc/mdy241
Annals of oncology, Vol. 29 (july 2018) , p. 1955-1963
|
|
|
9.
|
|
8 p, 257.6 KB |
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
/
Prat, A. (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Parker, J. S. (University of North Carolina. Lineberger Comprehensive Cancer Center) ;
Fan, C. (LUniversity of North Carolina. Lineberger Comprehensive Cancer Center) ;
Cheang, M. C. U. (University of North Carolina. Lineberger Comprehensive Cancer Center) ;
Miller, L. D. (Wake Forest School of Medicine. Department of Cancer Biology) ;
Bergh, Jonas (Manchester University. Department of Medical Oncology) ;
Chia, S. K. L. (British Columbia Cancer Agency) ;
Bernard, P. S. (University of Utah Health Sciences Center. Department of Pathology) ;
Nielsen, T. O. (University of British Columbia. Department of Pathology) ;
Ellis, M. J. (Siteman Cancer Center at Washington University. Department of Medicine) ;
Carey, L. A. (University of North Carolina. Deparment of Medicine) ;
Perou, Charles M. (University of North Carolina. Pathology & Laboratory Medicine)
ER-positive (ER+) breast cancer includes all of the intrinsic molecular subtypes, although the luminal A and B subtypes predominate. In this study, we evaluated the ability of six clinically relevant genomic signatures to predict relapse in patients with ER+ tumors treated with adjuvant tamoxifen only. [...]
2012 - 10.1093/annonc/mds080
Annals of oncology, Vol. 23 Núm. 11 (november 2012) , p. 2866-2873
|
|
|
10.
|
|
8 p, 500.4 KB |
Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer
/
Siena, S. (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ;
Sartore-Bianchi, A. (Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy) ;
García-Carbonero, Rocío (Universidad Complutense de Madrid) ;
Karthaus, M. (Department for Hematology and Oncology, Staedt Klinikum Neuperlach and Harlaching, Munich, Germany) ;
Smith, D. (Bordeaux University Hospital (França)) ;
Tabernero, Josep (Universitat Autònoma de Barcelona) ;
Van Cutsem, E. (KU Leuven, Leuven, Belgium) ;
Guan, X (Amgen Inc., Thousand Oaks, CA, USA) ;
Boedigheimer, M. (Amgen Inc., Thousand Oaks, CA, USA) ;
Ang, A. (Amgen Inc., Thousand Oaks, CA, USA) ;
Twomey, B. (Amgen Inc., Thousand Oaks, CA, USA) ;
Bach, B. A. (Amgen Inc., Thousand Oaks, CA, USA) ;
Jung, A. S. (Amgen Inc., Thousand Oaks, CA, USA) ;
Bardelli, Alberto (Department of Oncology, University of Torino, Candiolo, Italy)
Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status; however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution. [...]
2017 - 10.1093/annonc/mdx504
Annals of oncology, Vol. 29 (september 2017) , p. 119-126
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
